当前位置:循环首页>正文

[CIT2011]SPIDER PFO Closure: Results of the EU Study

作者:  HorstSievert   日期:2011/3/19 11:56:42

国际循环网版权所有,谢绝任何形式转载,侵犯版权者必予法律追究。

Patent foramen ovale (PFO) has been identified as a potential source of paradoxical embolism. Frequent forms of presentation of paradoxical embolism include cryptogenic stroke, peripheral embolism and decompression sickness in underwater divers.

 

  Patent foramen ovale (PFO) has been identified as a potential source of paradoxical embolism. Frequent forms of presentation of paradoxical embolism include cryptogenic stroke, peripheral embolism and decompression sickness in underwater divers. Transcatheter closure of PFO is a promising alternative to surgical closure or anticoagulation therapy to prevent paradoxical embolic events in patients with PFO. Several different devices have been used for transcatheter PFO closure. Dr Horst Sievert, Frankfurt, Germany, presented the results of the EU Study during Friday afternoons First Report Investigations session.
  The Spider PFO occluder (Lifetech Scientific (Shenzhen, China)) is a self-expandable, double disc device and is composed of a right disc of a ceramic coated Nitinol wire mesh and a left disc of an ePTFE membrane with four or six ceramic coated braided Nitinol anchors. The joint between the left and right discs allows them free rotation so the occluder can adapt to morphology. This will be the first device made in China to receive the CE mark.
  The EU Study enlisted 50 patients (18F, 32M) from March to December 2010 aged 21 to 76 years (mean 52 years) all with a prior neurological event (stroke or TIA). Procedures were performed under local anesthetic and followed up at one and six months with ECG, TEE and TCD. There were no procedural or technical complications experienced and implantation was successful in all cases. At one month follow up, there were no major adverse events but three short periods of atrial fibrillation had been experienced. TCD showed complete closure in 27 of the 50 patients and TEE showed all devices in position, no thrombus and complete closure in 34/50. At six months there were no new adverse events. TCD results were complete closure in 16 of 29 examined and TEE also showed all devices in position, no thrombus and complete closure of 18 of the 29 represented patients.
  The conclusions drawn from this study indicated that the ceramic nitinol may cause less thrombus formation and lead to faster endothelialization and improve bicompatability. Overall, initial results from this and the first-in-human trial of this device conducted by Dr Zhang et al (China), show that the device is safe. Further follow-up data is required to evaluate closure rates.

版面编辑:赵书芳  责任编辑:聂会珍


EU研究卵圆孔未闭PFO Horst Sievert

分享到: 更多


设为首页 | 加入收藏 | 关于我们 | 联系方式 | 招贤纳士
声明:国际循环网( www.icirculation.com)对刊载的所有文章、视频、幻灯、音频等资源拥有全部版权。未经本站许可,不得转载。
京ICP备15014970号-5  互联网药品信息服务资格证书编号(京)-非经营性-2017-0063  京公网安备 11010502033353号  增值电信业务经营许可证:京ICP证150541号
国际循环 版权所有   © 2004-2024 www.icirculation.com All Rights Reserved
公司名称:北京美赞广告有限公司 公司地址:北京市朝阳区朝阳门北大街乙12号天辰大厦1座1409 电话:010-51295530